1.53
-0.05(-3.16%)
Currency In USD
| Previous Close | 1.58 |
| Open | 1.57 |
| Day High | 1.58 |
| Day Low | 1.52 |
| 52-Week High | 6.08 |
| 52-Week Low | 1.05 |
| Volume | 508,812 |
| Average Volume | 1.57M |
| Market Cap | 48.28M |
| PE | -0.72 |
| EPS | -2.12 |
| Moving Average 50 Days | 2.11 |
| Moving Average 200 Days | 1.69 |
| Change | -0.05 |
If you invested $1000 in Acrivon Therapeutics, Inc. Common Stock (ACRV) since IPO date, it would be worth $91.95 as of February 21, 2026 at a share price of $1.53. Whereas If you bought $1000 worth of Acrivon Therapeutics, Inc. Common Stock (ACRV) shares 3 years ago, it would be worth $83.52 as of February 21, 2026 at a share price of $1.53.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory
GlobeNewswire Inc.
Feb 18, 2026 1:00 PM GMT
Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational and strategic benefits for internal and future partn
Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress
GlobeNewswire Inc.
Jan 23, 2026 1:11 PM GMT
Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, will highlight company’s recent interim clinical data from the ongoing, registrational-intent Phase 2b study of ACR-368 in subject
Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11
GlobeNewswire Inc.
Jan 08, 2026 12:30 PM GMT
Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 p